Published in Antimicrob Agents Chemother on September 01, 1986
Pharmacokinetics of ofloxacin after parenteral and oral administration. Antimicrob Agents Chemother (1987) 3.09
Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother (1993) 1.88
Comparative pharmacokinetics of new quinolones. Drugs (1987) 1.22
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother (1987) 1.17
Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis. Antimicrob Agents Chemother (2000) 1.03
Effect of dose on serum pharmacokinetics of intravenous ciprofloxacin with identification and characterization of extravascular compartments using noncompartmental and compartmental pharmacokinetic models. Antimicrob Agents Chemother (1987) 0.92
Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother (1990) 0.87
Relationships between renal function and disposition of oral ciprofloxacin. Antimicrob Agents Chemother (1988) 0.86
In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent. Antimicrob Agents Chemother (1984) 7.14
A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed (1979) 5.90
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA (1998) 4.99
Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother (1993) 4.76
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med (1993) 4.72
Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother (2011) 4.21
A controlled trial of early versus late treatment with zidovudine in symptomatic human immunodeficiency virus infection. Results of the Veterans Affairs Cooperative Study. N Engl J Med (1992) 3.34
Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother (2008) 3.09
Daptomycin: a novel agent for Gram-positive infections. Expert Opin Investig Drugs (1999) 2.83
Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother (1998) 2.59
Effect of 2',3'-didehydro-3'-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother (1994) 2.46
Gentamicin: in vitro studies. J Infect Dis (1969) 2.46
Emergence of resistance to imipenem in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 2.44
Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother (1984) 2.43
Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother (2001) 2.24
Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother (1998) 2.19
Comparative activity of tobramycin, amikacin, and gentamicin alone and with carbenicillin against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1974) 2.08
A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS (1996) 2.03
Multiple-dose pharmacokinetics of imipenem-cilastatin. Antimicrob Agents Chemother (1984) 1.98
Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1986) 1.97
Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother (1999) 1.90
Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1996) 1.89
Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother (1999) 1.77
Laboratory and clinical experience with cephalexin. Antimicrob Agents Chemother (Bethesda) (1968) 1.76
In vivo pharmacodynamics of torezolid phosphate (TR-701), a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob Agents Chemother (2011) 1.75
Normalization of hypertensive responses during ambulatory surgical stress by perioperative music. Psychosom Med (2001) 1.74
Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother (1998) 1.73
Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J Infect Dis (2007) 1.70
Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob Agents Chemother (2005) 1.69
Clinical pharmacology of carbenicillin compared with other penicillins. J Infect Dis (1970) 1.68
BL-P1654, ticarcillin, and carbenicillin: in vitro comparison alone and in combination with gentamicin against Pseudomonas aeruginosa. Antimicrob Agents Chemother (1975) 1.61
Piperacillin or ticarcillin plus amikacin. A double-blind prospective comparison of empiric antibiotic therapy for febrile granulocytopenic cancer patients. Am J Med (1981) 1.53
The acylampicillins: mezlocillin, piperacillin, and azlocillin. Rev Infect Dis (1984) 1.48
Multiple-dose pharmacokinetics of ciprofloxacin administered intravenously to normal volunteers. Antimicrob Agents Chemother (1985) 1.46
Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob Agents Chemother (2011) 1.46
Fluoroquinolone pharmacodynamics. Clin Infect Dis (2001) 1.45
Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum alpha 1 acid glycoprotein. J Infect Dis (1995) 1.43
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother (2011) 1.35
Integration of selected pharmacologic and microbiologic properties of three new beta-lactam antibiotics: a hypothesis for rational comparison. Rev Infect Dis (1984) 1.33
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother (2007) 1.33
The carbenicillin-gentamicin combination against Pseudomonas aeruginosa. Correlation of effect with gentamicin sensitivity. Ann Intern Med (1974) 1.33
A nationwide, multicenter, case-control study comparing risk factors, treatment, and outcome for vancomycin-resistant and -susceptible enterococcal bacteremia. Diagn Microbiol Infect Dis (2000) 1.32
Comparison of the pharmacokinetics of ceftazidime and moxalactam and their microbiological correlates in volunteers. Antimicrob Agents Chemother (1984) 1.31
Randomized trial of empiric antibiotic therapy with ticarcillin in combination with gentamicin, amikacin or netilmicin in febrile patients with granulocytopenia and cancer. Am J Med (1979) 1.31
An overview of the pharmacology of imipenem/cilastatin. J Antimicrob Chemother (1986) 1.31
Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene (2001) 1.29
A prospective randomized controlled trial of cefoxitin versus clindamycin-aminoglycoside in mixed anaerobic-aerobic infections. Surg Gynecol Obstet (1982) 1.28
Pharmacokinetic profile of imipenem/cilastatin in normal volunteers. Am J Med (1985) 1.28
Laboratory and clinical studies of carbenicillin against gram-negative bacilli. Antimicrob Agents Chemother (Bethesda) (1968) 1.27
The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression. Antimicrob Agents Chemother (2010) 1.27
Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother (1993) 1.26
Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin Pharmacol Ther (1990) 1.25
Pharmacodynamic evaluation of extending the administration time of meropenem using a Monte Carlo simulation. Antimicrob Agents Chemother (2005) 1.24
Pharmacokinetic studies of fluconazole in rabbits characterizing doses which achieve peak levels in serum and area under the concentration-time curve values which mimic those of high-dose fluconazole in humans. Antimicrob Agents Chemother (1998) 1.23
Effect of dose size on bioavailability of ciprofloxacin. Antimicrob Agents Chemother (1987) 1.22
Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside. Clin Microbiol Infect (2009) 1.22
Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob Agents Chemother (2006) 1.22
Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother (1993) 1.21
Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother (1999) 1.21
The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial. Neurology (1994) 1.21
Efficacy of constant infusion of A-77003, an inhibitor of the human immunodeficiency virus type 1 (HIV-1) protease, in limiting acute HIV-1 infection in vitro. Antimicrob Agents Chemother (1995) 1.20
Imipenem coadministered with cilastatin compared with moxalactam: integration of serum pharmacokinetics and microbiologic activity following single-dose administration to normal volunteers. Antimicrob Agents Chemother (1986) 1.18
An evaluation of optimal sampling strategy and adaptive study design. Clin Pharmacol Ther (1988) 1.18
Mechanisms responsible for plasma levels of nafcillin lower than those of oxacillin. Arch Intern Med (1970) 1.17
Pharmacokinetics of intravenously administered ciprofloxacin in patients with various degrees of renal function. Antimicrob Agents Chemother (1987) 1.17
Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets. Antimicrob Agents Chemother (2009) 1.16
Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med (1986) 1.15
The estimation of Widmark's factor. J Forensic Sci Soc (1986) 1.14
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. Antimicrob Agents Chemother (2008) 1.14
Development of staphylococci cross-resistant to cephalexin and methicillin. Antimicrob Agents Chemother (Bethesda) (1968) 1.13
Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother (1998) 1.12
Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm (2000) 1.12
The link between pharmacodynamics and physiologically based pharmacokinetic models. Clin Pharmacol Ther (2013) 1.12
Empiric antibiotic therapy for suspected infection in granulocytopenic cancer patients: a comparison between the combination of moxalactam plus amikacin and ticarcillin plus amikacin. Am J Med (1982) 1.12
Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob Agents Chemother (1987) 1.12
Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother (2009) 1.10
Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy (1995) 1.10
Regulation of CDC25B phosphatases subcellular localization. Oncogene (2000) 1.09
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers. Eur J Clin Microbiol (1984) 1.08
Pharmacokinetics and bioavailability of fluconazole in patients with AIDS. Antimicrob Agents Chemother (1993) 1.08